Section Arrow
MURA.NASDAQ
- Mural Oncology plc
Quotes are at least 15-min delayed:2025/04/14 09:57 EDT
Last
 1.04
+0.01 (+0.97%)
Day High 
1.0696 
Prev. Close
1.03 
1-M High
4.35 
Volume 
31.30K 
Bid
1.02
Ask
1.06
Day Low
1.01 
Open
1.01 
1-M Low
0.95 
Market Cap 
17.75M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.16 
20-SMA 2.04 
50-SMA 3.16 
52-W High 4.74 
52-W Low 0.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.58/-3.32
Enterprise Value
20.21M
Balance Sheet
Book Value Per Share
8.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PTNPalatin Technologies0.192+0.027+16.36%-- 
THTXTheratechnologies3.041+1.101+56.75%-- 
VERVVerve Therapeutics3.775+0.515+15.80%-- 
ARTLArtelo Biosciences1.2901+0.4682+56.97%-- 
RXRXRecursion Pharmaceuticals5.6014-0.1586-2.75%-- 
Quotes are at least 15-min delayed:2025/04/14 09:57 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.